Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-16T20:32:57.024Z Has data issue: false hasContentIssue false

Sexual adverse effects with new antidepressants

Published online by Cambridge University Press:  02 January 2018

Shameem Mir*
Affiliation:
Maudsley Hospital, Denmark Hill, London SE5 8AZ
David Taylor
Affiliation:
Maudsley Hospital, Denmark Hill, London SE5 8AZ
*
∗ Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Sexual dysfunction is a widely recognised adverse effect of many psychotropic agents. Older antidepressants such as monoamine oxidase inhibitors and tricycles, particularly clomipramine, are known to engender sexual adverse effects. In depression, this problem is exacerbated by the occurrence of impotence and lowered libido as part of depressive illness itself. We examined evidence relating to more recently introduced antidepressants: selective serotonin reuptake inhibitors, moclobemide, venlafaxine, nefazodone, mirtazapine and reboxetine. We reviewed published trials and case reports collated from searches of Medline, PsychLit and Micromedex from 1985 to December 1997, and contacted manufacturers of new antidepressants and requested information from them.

Information

Type
Drug information quarterly
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1998 The Royal College of Psychiatrists
Submit a response

eLetters

No eLetters have been published for this article.